Journal: Archives of Gynecology and Obstetrics

Article Title: Glycosylated fibronectin as a first trimester marker for gestational diabetes

doi: 10.1007/s00404-020-05670-8

Figure Lengend Snippet: a Glycosylated fibronectin concentrations in BMI subgroups of 20–25 and 30–35 kg/m 2 in the study and the control group. b Effect of smoking on concentrations of glycosylated fibronectin in the control and GDM groups. c Multiple of median (MoM) values for fibronectin and glycosylated fibronectin between control and GDM groups. d Multiple of median (MoM) values for adiponectin and glycosylated adiponectin between control and GDM groups

Article Snippet: Calibrators for both assays were made from recombinant human adiponectin (1065-AF, R&D Systems, Abingdon, UK).

Techniques: Control

Journal: Cell reports

Article Title: Npas4-mediated dopaminergic regulation of safety memory consolidation.

doi: 10.1016/j.celrep.2023.112678

Figure Lengend Snippet: Figure 4. Aberrant expression of CS memory precluded by upregulation of Npas4-Drd4 axis (A) A schematic diagram depicting CUT&Tag assay for Npas4 signaling. (B) Binding sites of Npas4 at the Drd4 promoter region delineated by CUT&Tag (top). Npas4 motif (TCGTG) within Npas4 peaks is highlighted (yellow, bottom). They axis indicates normalized reads (107). (C) Wild-type (WT) or mutant Drd4 promoter-containing probes used for luciferase assays: ①the WT Drd4 promoter, ②the mutant promoter lacking postulated Npas4 motif, and ③the mutant promoter lacking Npas4 binding sites identified by CUT&Tag assay (left). Drd4 promoter activity (relative to activity with empty vector) was analyzed for each condition (right) (①, n = 6; ②, n = 6; ③, n = 6 wells; one-way ANOVA with Tukey’s post hoc test, ****p < 0.0001).

Article Snippet: We also perfused a Drd4 agonist (PD-168,077, 200 nM, 1065, Tocris), Drd1/Drd5 agonist (SKF 38393, 10 mM), or Drd4 antagonist (L-745,870, 50 nM, Tocris) to examine the dopaminergic signaling.

Techniques: Expressing, Binding Assay, Mutagenesis, Luciferase, Activity Assay, Plasmid Preparation

Journal: Cell reports

Article Title: Npas4-mediated dopaminergic regulation of safety memory consolidation.

doi: 10.1016/j.celrep.2023.112678

Figure Lengend Snippet: Figure 5. Drd4-induced depotentiation of the LA-to-aBA pathway (A) Effects of Drd4 agonist (PD-168,077) on synaptic transmission of the LA-to-aBA pathway of naive or saline- or CORT-injected mice at the LTM time point. Insets: representative traces of EPSCs at the color-designated time points (naive, n = 8; saline-LTM, n = 9; CORT-LTM, n = 8 cells). (B) PPR measurement (250 ms) of the evoked EPSCs before (left) and after PD-168,077 application (right) (naive, n = 8; saline-LTM, n = 9; CORT-LTM, n = 8 cells; one-way ANOVA with Tuckey’s post hoc test, *p = 0.0498, **p = 0.0015). (C) Schematic (top) and an experimental timeline (bottom) for in vivo recording of fEPSPs from the aBA while stimulating LA axon terminals. (D) fEPSP slopes before and after discriminative FC with CORT injection were measured with/without subsequent treatment of PD-168,077 (vehicle, n = 6; Drd4 agonist, n = 6 mice). (E) Averaged fEPSP slopes for each recording session (vehicle, n = 6; Drd4 agonist, n = 6 mice; one-way RM ANOVA with Tuckey’s post hoc test, *p = 0.0189). (F) An experimental timeline for micro-infusion of either Drd4 agonist (PD-168,077) or vehicle into the LA of animals that underwent discriminative FC and CORT injection and behavioral tests. (G) Effect of PD-168,077 micro-infusion on fear retrieval in the cue test (vehicle, n = 8; Drd4 agonist, n = 7 mice; interaction of tone frequency and group: two-way RM ANOVA, F = 16.68, ****p < 0.0001, followed by Sidak’s post hoc test, ****p < 0.0001). Data are shown as mean ± SEM. See also Figure S9.

Article Snippet: We also perfused a Drd4 agonist (PD-168,077, 200 nM, 1065, Tocris), Drd1/Drd5 agonist (SKF 38393, 10 mM), or Drd4 antagonist (L-745,870, 50 nM, Tocris) to examine the dopaminergic signaling.

Techniques: Transmission Assay, Saline, Injection, In Vivo

Journal: Cell reports

Article Title: Npas4-mediated dopaminergic regulation of safety memory consolidation.

doi: 10.1016/j.celrep.2023.112678

Figure Lengend Snippet: Figure 6. Retrievability of CS memory regulated by activity of Npas4-expressing neurons (A) A descriptive diagram for Npas4-Drd4 signaling and manipulation of Npas4-expressing neurons, which determine the expression of CS memory. (B) Schematic for labeling and activity manipulation of N-RAM-labeled neurons in the LA (left). Representative images for N-RAM labeling and DREADD expression within the LA areas outlined by dotted lines (right). Scale bars, 50 mm. (C) DREADD-expressing neurons relative to DAPI staining at each group (top, home cage, n = 5; FC, n = 9; FC + Dox on, n = 6 mice; one-way ANOVA with Tuckey’s post hoc test, **p = 0.0062, ****p < 0.0001). Colocalization ratios of DREADD-expressing neurons denoted with mCherry and N-RAM-labeled neurons denoted with EYFP between home cage and FC groups (bottom, home cage, n = 5; FC, n = 9 mice). (D) Activity manipulation of Npas4-expressing neurons in the generalization test (mCherry, n = 7; hM3Dq, n = 9; hM4Di, n = 7 mice; interaction of tone frequency and group: two-way RM ANOVA, F = 2.55, **p = 0.0088, followed by Tuckey’s post hoc test, **p < 0.01). (E) Schematic for labeling of c-Fos- and Npas4-expressing cells in the LA (left). Representative images for engram neurons expressing either Npas4 or c-Fos after FC (right). White arrows indicate colabeled neurons for c-Fos and Npas4. Scale bars, 50 mm. (F) Ratios of singularly and colabeled neurons within the LA (n = 5 mice). Data are shown as mean ± SEM. See also Figure S10.

Article Snippet: We also perfused a Drd4 agonist (PD-168,077, 200 nM, 1065, Tocris), Drd1/Drd5 agonist (SKF 38393, 10 mM), or Drd4 antagonist (L-745,870, 50 nM, Tocris) to examine the dopaminergic signaling.

Techniques: Activity Assay, Expressing, Labeling, Staining

Journal: Cancer Prevention Research

Article Title: Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care

doi: 10.1158/1940-6207.capr-11-0508

Figure Lengend Snippet: Figure 5. [A] Effect of detecting antibody incubation times on the slope and SNR of the CA125 p-BNCs. Decrease in incubation time resulted in improved immunoassay slope along with corresponding increase in precision shown by the error bars. [B] Effect of sample incubation flow rates on the slope of the CA 125 immunoassay. Initial increase in flow rate resulted in a steep increase in slope through 750 mL/min (optimal flow rate) for the optimal capturing antibody concentration (320 ng/bead) and then leveled off. Similar trends were also noted for other capturing antibody concentrations.

Article Snippet: Anti-CA125 monoclonal antibodies (Clones M002201, M002203, M77161, M8072320, M8072321, andM8072322) were obtained from Fitzgerald Industries International.

Techniques: Incubation, Concentration Assay

Journal: Cancer Prevention Research

Article Title: Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Toward Ovarian Cancer Diagnostics at the Point-of-Care

doi: 10.1158/1940-6207.capr-11-0508

Figure Lengend Snippet: Figure 6. [A] Dose-response curve for CA125 quantification on the p-BNCs over 10 to 400 U/mL concentration range. [B] Plot showing good correlation between the p-BNCs and FDA-approved ELISA for values of CA125 measured in the sera of patients with advanced- stage epithelial ovarian cancer.

Article Snippet: Anti-CA125 monoclonal antibodies (Clones M002201, M002203, M77161, M8072320, M8072321, andM8072322) were obtained from Fitzgerald Industries International.

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay